Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Regeneron Pharmaceuticals Inc    REGN

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Regeneron: Sanofi Plans to Increase Stake to Over $500 Million of Stock

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/11/2013 | 04:44pm CET
   By Melodie Warner 
 

Regeneron Pharmaceuticals Inc. (>> Regeneron Pharmaceuticals Inc) said Sanofi S.A. (SNY, SAN.FR) notified the biopharmaceutical company of its intent to boost its investment in the company and push its ownership of voting securities to more than $500 million.

Sanofi currently holds about 17% of Regeneron's shares outstanding, according to FactSet Research.

Regeneron said a December 2007 investor agreement bonds the French drug maker to certain standstill provisions, including an agreement not to acquire more than 30% of Regeneron's Class A stock and common stock outstanding.

Regeneron said these standstill provisions are in effect until the fifth anniversary of the expiration of a license and collaboration agreement between the companies.

Sanofi and Regeneron have worked together on experimental cancer drug Zaltrap, among other things.

Shares of Regeneron rose 5.6% to $175.13 in recent trading and have climbed 24% in the past three months.

Write to Melodie Warner at melodie.warner@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : Regeneron Pharmaceuticals Inc
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on REGENERON PHARMACEUTICALS
01:01a REGENERON PHARMACEUTICALS : U.K. Biobank, Regeneron and GSK Announce Largest Gen..
03/17DJAmgen's Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- Update
03/17DJAmgen's Repatha Study Shows Reduced Risk of Heart Attack, Stroke
03/16 REGENERON PHARMACEUTICALS : Patent Issued for Genetically Modified Major Histoco..
03/16 REGENERON PHARMACEUTICALS : Researchers Submit Patent Application, "Humanized Il..
03/16 REGENERON PHARMACEUTICALS : and Sanofi to Present New Phase 3 Praluent® alirocum..
03/15 REGENERON PHARMACEUTICALS : Teen Scientist Researches New Approach to Neurologic..
03/15 REGENERON PHARMACEUTICALS : Teen Scientist Researches New Approach to Neurologic..
03/09 REGENERON PHARMACEUTICALS : Patent Issued for VEGF Antagonist Formulations Suita..
03/09 NASDAQ 100 MOVERS : Stx, regn
More news
Sector news : Bio Therapeutic Drugs
03/18DJAMGEN : Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- 3rd Update
03/17DJAMGEN : Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- 2nd Update
03/17DJAMGEN : Money-Back Guarantee
03/17DJAmgen's Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- Update
03/17DJAmgen's Repatha Study Shows Reduced Risk of Heart Attack, Stroke
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
03/21 Sanofi, Regeneron sue Amgen over eczema drug
03/21 AMERICAN COLLEGE OF CARDIOLOGY : No Repatha Of Glory
03/21 Aggressive Payers Block Access To PCSK9s
03/17 AMGEN TANKS ON REPATHA DATA : Analysis
03/13 Investors await details of Amgen's CVOT data for cholesterol med Repatha on F..
Advertisement
Financials ($)
Sales 2017 5 481 M
EBIT 2017 2 150 M
Net income 2017 1 011 M
Finance 2017 1 490 M
Yield 2017 -
P/E ratio 2017 43,52
P/E ratio 2018 33,95
EV / Sales 2017 6,91x
EV / Sales 2018 5,70x
Capitalization 39 354 M
More Financials
Chart REGENERON PHARMACEUTICALS
Duration : Period :
Regeneron Pharmaceuticals  Technical Analysis Chart | REGN | US75886F1075 | 4-Traders
Full-screen chart
Technical analysis trends REGENERON PHARMAC...
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 423 $
Spread / Average Target 14%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Leonard S. Schleifer President, Chief Executive Officer & Director
George Damis Yancopoulos President, Director & Chief Scientific Officer
P. Roy Vagelos Chairman
Robert E. Landry Chief Financial Officer & Senior VP-Finance
Neil Stahl Executive VP-Research & Development
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
REGENERON PHARMACEUTIC..1.06%39 354
AMGEN, INC.14.12%122 877
CELGENE CORPORATION6.97%96 328
GILEAD SCIENCES, INC.-5.40%88 541
ACTELION LTD25.17%29 641
VERTEX PHARMACEUTICALS..21.49%22 235
More Results